Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial

NCT04966481 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04966481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial
Lead sponsor
Washington University School of Medicine
Phase
Phase 3
Overall status
Recruiting
Start date
April 6, 2022
Completion date
February 28, 2029
Enrollment
81 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hpv-unrelated head and neck squamous cell carcinoma